Filing Details
- Accession Number:
- 0001415889-24-019071
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-07-02 21:05:19
- Reporting Period:
- 2024-06-28
- Accepted Time:
- 2024-07-02 21:05:19
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1604821 | Natera Inc. | NTRA | Services-Medical Laboratories (8071) | 010894487 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1711968 | Leonard Steven Chapman | C/O Natera, Inc. 13011 Mccallen Pass Building A Suite 100 Austin TX 78753 | Ceo And President | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-06-28 | 37,500 | $0.00 | 250,851 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-07-01 | 24,008 | $107.73 | 226,843 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-07-01 | 11,061 | $108.61 | 215,782 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-07-01 | 2,431 | $109.43 | 213,351 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Unit | Disposition | 2024-06-28 | 37,500 | $0.00 | 37,500 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 37,500 | No | 4 | M | Direct |
Footnotes
- Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Common Stock.
- The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.21 to $108.17 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.25 to $109.23 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.27 to $109.66 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- On January 22, 2021, the Reporting Person was granted RSUs covering 75,000 shares of Common Stock which vest in tranches upon the Reporting Person achieving certain milestones relating to a combination of the passage of time and the Reporting Person achieving certain milestones relating to the Issuer's stock price. On June 28, 2024, the criteria was satisfied for the vesting of RSUs covering 37,500 shares of Common Stock.
Billionaire Hedge Funds
